$PODD
INSULET CORP Stock $podd

$podd Overview Financials Valuation SEC Filings Company Website

2017 Q2 Form 10-Q Financial Statement

#000114519717000009 Filed on May 09, 2017

Income Statement

Concept	2017 Q2	2017 Q1	2016 Q1
Revenue	$109.8M	$101.7M	$81.21M
YoY Change	25.68%	25.24%	68.67%
Cost Of Revenue	$45.12M	$42.32M	$37.16M
YoY Change	22.36%	13.87%	96.05%
Gross Profit	$64.64M	$59.40M	$44.05M
YoY Change	28.11%	34.84%	50.9%
Gross Profit Margin	58.89%	58.4%	54.24%
Selling, General & Admin	$49.97M	$47.21M	$38.76M
YoY Change	28.81%	21.79%	37.2%
% of Gross Profit	77.3%	79.47%	87.99%
Research & Development	$18.03M	$17.50M	$12.99M
YoY Change	39.19%	34.73%	58.27%
% of Gross Profit	27.89%	29.46%	29.49%
Depreciation & Amortization	$3.390M	$3.323M	$3.422M
YoY Change	-1.17%	-2.89%	-0.32%
% of Gross Profit	5.24%	5.59%	7.77%
Operating Expenses	$68.00M	$64.71M	$51.75M
YoY Change	31.41%	25.04%	41.94%
Operating Profit	-$3.358M	-$5.308M	-$7.699M
YoY Change	160.71%	-31.06%	5.96%
Interest Expense	-$4.300M	-$4.600M	-$2.900M
YoY Change	43.33%	58.62%	-9.38%
% of Operating Profit
Other Income/Expense, Net	-$4.308M	-$4.573M	-$2.926M
YoY Change	43.7%	56.29%	-7.17%
Pretax Income	-$7.666M	-$9.881M	-$10.63M
YoY Change	78.86%	-7.0%	1.99%
Income Tax	$101.0K	$96.00K	$100.0K
% Of Pretax Income
Net Earnings	-$7.767M	-$9.977M	-$12.48M
YoY Change	85.02%	-20.06%	5.47%
Net Earnings / Revenue	-7.08%	-9.81%	-15.37%
Basic Earnings Per Share
Diluted Earnings Per Share	-$134.5K	-$173.3K	-$219.3K
COMMON SHARES
Basic Shares Outstanding	57.92M shares	57.65M shares	57.02M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2017 Q2	2017 Q1	2016 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$258.6M	$254.0M	$111.6M
YoY Change	132.35%	127.6%	-23.35%
Cash & Equivalents	$73.49M	$76.04M	$111.6M
Short-Term Investments	$185.1M	$178.0M
Other Short-Term Assets	$8.400M	$8.200M	$5.700M
YoY Change	23.53%	43.86%	54.05%
Inventory	$33.96M	$34.33M	$14.02M
Prepaid Expenses
Receivables	$37.75M	$40.65M	$40.47M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$338.7M	$337.2M	$171.8M
YoY Change	86.85%	96.2%	-16.35%
LONG-TERM ASSETS
Property, Plant & Equipment	$75.88M	$65.28M	$41.70M
YoY Change	84.48%	56.56%	-6.54%
Goodwill	$39.76M	$39.70M	$39.76M
YoY Change	-0.01%	-0.16%	5.93%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$1.559M	$605.0K	$588.0K
YoY Change	1671.59%	2.89%	-88.21%
Total Long-Term Assets	$120.6M	$107.8M	$82.93M
YoY Change	47.49%	29.98%	-17.31%
TOTAL ASSETS
Total Short-Term Assets	$338.7M	$337.2M	$171.8M
Total Long-Term Assets	$120.6M	$107.8M	$82.93M
Total Assets	$459.3M	$445.0M	$254.8M
YoY Change	74.62%	74.65%	-16.66%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$12.24M	$6.413M	$13.48M
YoY Change	-43.33%	-52.43%	-5.36%
Accrued Expenses	$34.65M	$31.84M	$30.39M
YoY Change	15.73%	4.79%	20.26%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due			$4.400M
YoY Change			-26.67%
Total Short-Term Liabilities	$48.02M	$39.38M	$49.78M
YoY Change	-12.98%	-20.89%	5.06%
LONG-TERM LIABILITIES
Long-Term Debt	$340.8M	$336.8M	$173.7M
YoY Change	94.0%	93.9%	1.81%
Other Long-Term Liabilities	$5.748M	$5.231M	$4.922M
YoY Change	21.52%	6.28%	62.01%
Total Long-Term Liabilities	$346.6M	$342.0M	$178.6M
YoY Change	92.1%	91.48%	2.86%
TOTAL LIABILITIES
Total Short-Term Liabilities	$48.02M	$39.38M	$49.78M
Total Long-Term Liabilities	$346.6M	$342.0M	$178.6M
Total Liabilities	$394.6M	$381.4M	$228.4M
YoY Change	67.49%	66.99%	1.51%
SHAREHOLDERS EQUITY
Retained Earnings	-$698.2M	-$690.4M	-$664.0M
YoY Change	4.48%	3.97%	12.57%
Common Stock	$58.00K	$58.00K	$57.00K
YoY Change	1.75%	1.75%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$64.73M	$63.59M	$26.40M
YoY Change
Total Liabilities & Shareholders Equity	$459.3M	$445.0M	$254.8M
YoY Change	74.62%	74.65%	-16.66%

Cashflow Statement

Concept	2017 Q2	2017 Q1	2016 Q1
OPERATING ACTIVITIES
Net Income	-$7.767M	-$9.977M	-$12.48M
YoY Change	85.02%	-20.06%	5.47%
Depreciation, Depletion And Amortization	$3.390M	$3.323M	$3.422M
YoY Change	-1.17%	-2.89%	-0.32%
Cash From Operating Activities	$17.97M	-$21.84M	-$10.52M
YoY Change	388.32%	107.62%	201.52%
INVESTING ACTIVITIES
Capital Expenditures	-$13.39M	$25.68M	$3.160M
YoY Change	386.91%	712.63%	-27.29%
Acquisitions
YoY Change
Other Investing Activities	-$8.590M	-$16.61M	$4.610M
YoY Change	-75.09%	-460.3%
Cash From Investing Activities	-$21.98M	-$42.29M	$1.454M
YoY Change	-40.98%	-3008.25%	-133.46%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$6.335M	$796.0K
YoY Change		695.85%	-83.68%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	1.260M	$2.927M	-$2.184M
YoY Change	-152.28%	-234.02%	-197.11%
NET CHANGE
Cash From Operating Activities	17.97M	-$21.84M	-$10.52M
Cash From Investing Activities	-21.98M	-$42.29M	$1.454M
Cash From Financing Activities	1.260M	$2.927M	-$2.184M
Net Change In Cash	-2.750M	-$61.19M	-$11.25M
YoY Change	-92.35%	444.09%	101.38%
FREE CASH FLOW
Cash From Operating Activities	$17.97M	-$21.84M	-$10.52M
Capital Expenditures	-$13.39M	$25.68M	$3.160M
Free Cash Flow	$31.36M	-$47.51M	-$13.68M
YoY Change	387.71%	247.4%	74.59%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2017Q1	dei	Amendment Flag AmendmentFlag	false
CY2017Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2017Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2017Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2017
CY2017Q1	dei	Document Period End Date DocumentPeriodEndDate	2017-03-31
CY2017Q1	dei	Document Type DocumentType	10-Q
CY2017Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001145197
CY2017Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	57916580	shares
CY2017Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2017Q1	dei	Entity Registrant Name EntityRegistrantName	INSULET CORP
CY2017Q1	dei	Trading Symbol TradingSymbol	PODD
CY2016Q1	podd	Debt Instrument Stated Coupon Rate Interest Expense DebtInstrumentStatedCouponRateInterestExpense	1006000	USD
CY2017Q1	podd	Debt Instrument Stated Coupon Rate Interest Expense DebtInstrumentStatedCouponRateInterestExpense	1413000	USD
CY2017Q1	podd	Finited Lived Intangible Assets Excluding Software In Process Of Development Net FinitedLivedIntangibleAssetsExcludingSoftwareInProcessOfDevelopmentNet	1644000	USD
CY2016Q1	podd	Increase Decrease In Accounts Payable Accrued Expenses And Other Liabilities IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities	-8776000	USD
CY2017Q1	podd	Increase Decrease In Accounts Payable Accrued Expenses And Other Liabilities IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities	-14226000	USD
CY2016Q1	podd	Interestand Other Expense Total InterestandOtherExpenseTotal	2990000	USD
CY2017Q1	podd	Interestand Other Expense Total InterestandOtherExpenseTotal	5407000	USD
CY2017Q1	podd	Number Of Financial Institution NumberOfFinancialInstitution	1	location
CY2017Q1	podd	Number Of Inches Of Tubing In Conventional Insulin Pump NumberOfInchesOfTubingInConventionalInsulinPump	42	in
CY2016	podd	Percentage Of Accounts Payable Accrued Expensesand Other Current Liabilities PercentageOfAccountsPayableAccruedExpensesandOtherCurrentLiabilities	0.16
CY2017Q1	podd	Percentage Of Accounts Payable Accrued Expensesand Other Current Liabilities PercentageOfAccountsPayableAccruedExpensesandOtherCurrentLiabilities	0.09
CY2017Q1	podd	Return Period ReturnPeriod	P45D
CY2017Q1	podd	Return Period Canada ReturnPeriodCanada	P90D
CY2016Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	41228000	USD
CY2016Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	41228000	USD
CY2017Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	31839000	USD
CY2016Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	13160000	USD
CY2017Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	6413000	USD
CY2016Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	2886000	USD
CY2017Q1	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	1893000	USD
CY2016Q4	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	31714000	USD
CY2017Q1	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	43348000	USD
CY2016Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	28803000	USD
CY2017Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	40648000	USD
CY2017Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	31839000	USD
CY2016Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	6753000	USD
CY2017Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	7300000	USD
CY2016Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	21999000	USD
CY2017Q1	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	15051000	USD
CY2016Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	39000000	USD
CY2017Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	42000000	USD
CY2016Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-726000	USD
CY2017Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-657000	USD
CY2017Q1	us-gaap	Acquired Finite Lived Intangible Assets Weighted Average Useful Life AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife	P2Y6M
CY2016Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	744243000	USD
CY2017Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	754585000	USD
CY2016Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5271000	USD
CY2017Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	7124000	USD
CY2016Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	2911000	USD
CY2017Q1	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	2700000	USD
CY2016Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	1702000	USD
CY2017Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	3504000	USD
CY2016Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	282000	USD
CY2017Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	490000	USD
CY2016Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	1984000	USD
CY2017Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	3994000	USD
CY2016Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	100000	USD
CY2017Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	300000	USD
CY2016Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9072274	shares
CY2017Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	11948332	shares
CY2016Q4	us-gaap	Assets Assets	456647000	USD
CY2017Q1	us-gaap	Assets Assets	444957000	USD
CY2016Q4	us-gaap	Assets Current AssetsCurrent	369960000	USD
CY2017Q1	us-gaap	Assets Current AssetsCurrent	337168000	USD
CY2016Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	161396000	USD
CY2017Q1	us-gaap	Available For Sale Securities AvailableForSaleSecurities	177990000	USD
CY2016Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	USD
CY2017Q1	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	3000	USD
CY2016Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	207000	USD
CY2017Q1	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	220000	USD
CY2016Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	161603000	USD
CY2017Q1	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	178207000	USD
CY2016Q4	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	161396000	USD
CY2017Q1	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	177990000	USD
CY2017Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1700000	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	122672000	USD
CY2016Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	111635000	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	137174000	USD
CY2017Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	76038000	USD
CY2016Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-11037000	USD
CY2017Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-61136000	USD
CY2016Q1	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	2000000	USD
CY2017Q1	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	0	USD
CY2016Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2017Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2017Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	57457967	shares
CY2017Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	57912745	shares
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	57457967	shares
CY2017Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	57912745	shares
CY2016Q4	us-gaap	Common Stock Value CommonStockValue	57000	USD
CY2017Q1	us-gaap	Common Stock Value CommonStockValue	58000	USD
CY2016Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-12081000	USD
CY2017Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-9908000	USD
CY2016Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	37162000	USD
CY2017Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	42315000	USD
CY2016Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	69684000	USD
CY2017Q1	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	66180000	USD
CY2016Q4	us-gaap	Deferred Finance Costs Noncurrent Net DeferredFinanceCostsNoncurrentNet	9632000	USD
CY2017Q1	us-gaap	Deferred Finance Costs Noncurrent Net DeferredFinanceCostsNoncurrentNet	9142000	USD
CY2016Q4	us-gaap	Deferred Revenue DeferredRevenue	1900000	USD
CY2017Q1	us-gaap	Deferred Revenue DeferredRevenue	1800000	USD
CY2016Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	1309000	USD
CY2017Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	1127000	USD
CY2016Q1	us-gaap	Depreciation And Amortization Discontinued Operations DepreciationAndAmortizationDiscontinuedOperations	100000	USD
CY2017Q1	us-gaap	Depreciation And Amortization Discontinued Operations DepreciationAndAmortizationDiscontinuedOperations	0	USD
CY2016Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3422000	USD
CY2017Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3323000	USD
CY2016Q1	us-gaap	Discontinued Operation Gain Loss On Disposal Of Discontinued Operation Net Of Tax Per Basic And Diluted Share DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare	-0.03
CY2017Q1	us-gaap	Discontinued Operation Gain Loss On Disposal Of Discontinued Operation Net Of Tax Per Basic And Diluted Share DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare	0.00
CY2016Q1	us-gaap	Discontinued Operation Intra Entity Amounts Discontinued Operation After Disposal Expense DiscontinuedOperationIntraEntityAmountsDiscontinuedOperationAfterDisposalExpense	300000	USD
CY2017Q1	us-gaap	Discontinued Operation Intra Entity Amounts Discontinued Operation After Disposal Expense DiscontinuedOperationIntraEntityAmountsDiscontinuedOperationAfterDisposalExpense	0	USD
CY2017Q1	us-gaap	Discontinued Operation Period Of Continuing Involvement After Disposal DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal	P0Y6M0D
CY2016Q1	us-gaap	Discontinued Operation Tax Effect Of Discontinued Operation DiscontinuedOperationTaxEffectOfDiscontinuedOperation	408000	USD
CY2017Q1	us-gaap	Discontinued Operation Tax Effect Of Discontinued Operation DiscontinuedOperationTaxEffectOfDiscontinuedOperation	0	USD
CY2016Q1	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	210000	USD
CY2017Q1	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	58000	USD
CY2017Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	56498000	USD
CY2016Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	4017000	USD
CY2017Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	4274000	USD
CY2017Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	623000	USD
CY2017Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	644000	USD
CY2017Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	68000	USD
CY2017Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	309000	USD
CY2016Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	6058000	USD
CY2017Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	6482000	USD
CY2016Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	2041000	USD
CY2017Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	2208000	USD
CY2016Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	0	USD
CY2017Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	0	USD
CY2016Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	14739000	USD
CY2017Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	19111000	USD
CY2016Q4	us-gaap	Goodwill Goodwill	39677000	USD
CY2017Q1	us-gaap	Goodwill Goodwill	39697000	USD
CY2016Q1	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2017Q1	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2016Q1	us-gaap	Gross Profit GrossProfit	44051000	USD
CY2017Q1	us-gaap	Gross Profit GrossProfit	59398000	USD
CY2016Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-10625000	USD
CY2017Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-9881000	USD
CY2016Q1	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-10689000	USD
CY2017Q1	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-9977000	USD
CY2016Q1	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-0.19
CY2017Q1	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-0.17
CY2016Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-1792000	USD
CY2017Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	0	USD
CY2016Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	64000	USD
CY2016Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	100000	USD
CY2017Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	96000	USD
CY2017Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	100000	USD
CY2016Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-2306000	USD
CY2017Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	12146000	USD
CY2016Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-882000	USD
CY2017Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-87000	USD
CY2016Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2649000	USD
CY2017Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-1175000	USD
CY2017Q1	us-gaap	Interest Expense Debt InterestExpenseDebt	5007000	USD
CY2016Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	17922000	USD
CY2017Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	19124000	USD
CY2016Q4	us-gaap	Inventory Net InventoryNet	35514000	USD
CY2016Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	956000	USD
CY2017Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	111000	USD
CY2016Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	462000	USD
CY2017Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1421000	USD
CY2016Q1	us-gaap	Interest Expense Debt InterestExpenseDebt	3096000	USD
CY2017Q1	us-gaap	Inventory Net InventoryNet	34333000	USD
CY2016Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	1911000	USD
CY2017Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	2284000	USD
CY2016Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	15681000	USD
CY2017Q1	us-gaap	Inventory Work In Process InventoryWorkInProcess	12925000	USD
CY2016Q1	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	600000	USD
CY2017Q1	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	600000	USD
CY2016Q4	us-gaap	Liabilities Liabilities	393497000	USD
CY2017Q1	us-gaap	Liabilities Liabilities	381372000	USD
CY2016Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	456647000	USD
CY2017Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	444957000	USD
CY2016Q4	us-gaap	Liabilities Current LiabilitiesCurrent	55697000	USD
CY2017Q1	us-gaap	Liabilities Current LiabilitiesCurrent	39379000	USD
CY2016Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	332768000	USD
CY2017Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	336762000	USD
CY2015Q4	us-gaap	Loss Contingency Accrual Carrying Value Current LossContingencyAccrualCarryingValueCurrent	400000	USD
CY2016Q4	us-gaap	Loss Contingency Accrual Carrying Value Current LossContingencyAccrualCarryingValueCurrent	300000	USD
	us-gaap	Loss Contingency Claims Dismissed Number LossContingencyClaimsDismissedNumber	2	LegalMatter
CY2015Q2	us-gaap	Loss Contingency New Claims Filed Number LossContingencyNewClaimsFiledNumber	3	LegalMatter
CY2016Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-2184000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2927000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	1454000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-42286000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-10517000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-21835000	USD
CY2016Q1	us-gaap	Net Income Loss NetIncomeLoss	-12481000	USD
CY2017Q1	us-gaap	Net Income Loss NetIncomeLoss	-9977000	USD
CY2016Q4	us-gaap	Noncurrent Assets NoncurrentAssets	44969000	USD
CY2017Q1	us-gaap	Noncurrent Assets NoncurrentAssets	65512000	USD
CY2016Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2926000	USD
CY2017Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-4573000	USD
CY2017Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2016Q1	us-gaap	Operating Expenses OperatingExpenses	51750000	USD
CY2017Q1	us-gaap	Operating Expenses OperatingExpenses	64706000	USD
CY2016Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-7699000	USD
CY2017Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-5308000	USD
CY2017Q1	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	14346000	USD
CY2017Q1	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	2684000	USD
CY2017Q1	us-gaap	Operating Leases Future Minimum Payments Due In Rolling Year Four OperatingLeasesFutureMinimumPaymentsDueInRollingYearFour	2383000	USD
CY2017Q1	us-gaap	Operating Leases Future Minimum Payments Due In Rolling Year Three OperatingLeasesFutureMinimumPaymentsDueInRollingYearThree	2402000	USD
CY2017Q1	us-gaap	Operating Leases Future Minimum Payments Due In Rolling Year Two OperatingLeasesFutureMinimumPaymentsDueInRollingYearTwo	2681000	USD
CY2017Q1	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	2131000	USD
CY2017Q1	us-gaap	Operating Leases Future Minimum Payments Remainder Of Fiscal Year OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear	2065000	USD
CY2016Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	7948000	USD
CY2017Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	5890000	USD
CY2016Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	216000	USD
CY2017Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	605000	USD
CY2016Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	400000	USD
CY2017Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	79000	USD
CY2016Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	400000	USD
CY2017Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	69000	USD
CY2016Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	0	USD
CY2017Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-10000	USD
CY2016Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	5032000	USD
CY2017Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	5231000	USD
CY2016Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	170000	USD
CY2017Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	434000	USD
CY2016Q1	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	139000	USD
CY2017Q1	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	0	USD
CY2016Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	1640000	USD
CY2017Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	3139000	USD
CY2016Q1	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	0	USD
CY2017Q1	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	41347000	USD
CY2016Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3160000	USD
CY2017Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	25679000	USD
CY2016Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2017Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2016Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2017Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2016Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2017Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2016Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2017Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2016Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2017Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2016Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	7073000	USD
CY2017Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	8159000	USD
CY2016Q1	us-gaap	Proceeds From Divestiture Of Interest In Consolidated Subsidiaries ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries	4614000	USD
CY2017Q1	us-gaap	Proceeds From Divestiture Of Interest In Consolidated Subsidiaries ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries	0	USD
CY2016Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	796000	USD
CY2017Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	6335000	USD
CY2016Q1	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	0	USD
CY2017Q1	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	24740000	USD
CY2015Q4	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	4152000	USD
CY2016Q1	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	4160000	USD
CY2016Q4	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	4388000	USD
CY2017Q1	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	4562000	USD
CY2016Q4	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	1642000	USD
CY2017Q1	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	1705000	USD
CY2016Q4	us-gaap	Product Warranty Accrual Noncurrent ProductWarrantyAccrualNoncurrent	2746000	USD
CY2017Q1	us-gaap	Product Warranty Accrual Noncurrent ProductWarrantyAccrualNoncurrent	2857000	USD
CY2016Q1	us-gaap	Product Warranty Accrual Payments ProductWarrantyAccrualPayments	1020000	USD
CY2017Q1	us-gaap	Product Warranty Accrual Payments ProductWarrantyAccrualPayments	1289000	USD
CY2016Q1	us-gaap	Product Warranty Accrual Warranties Issued ProductWarrantyAccrualWarrantiesIssued	1028000	USD
CY2017Q1	us-gaap	Product Warranty Accrual Warranties Issued ProductWarrantyAccrualWarrantiesIssued	1463000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	44753000	USD
CY2017Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	65279000	USD
CY2016Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	655000	USD
CY2017Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	295000	USD
CY2016Q1	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	1340000	USD
CY2017Q1	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	269000	USD
CY2016Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	12989000	USD
CY2017Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	17500000	USD
CY2016Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	1200000	USD
CY2017Q1	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	1200000	USD
CY2016Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-680424000	USD
CY2017Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-690401000	USD
CY2016Q1	us-gaap	Revenues Revenues	81213000	USD
CY2017Q1	us-gaap	Revenues Revenues	101713000	USD
CY2016Q1	us-gaap	Sales Revenue Net SalesRevenueNet	81213000	USD
CY2017Q1	us-gaap	Sales Revenue Net SalesRevenueNet	101713000	USD
CY2016Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	24022000	USD
CY2017Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	28095000	USD
CY2016Q1	us-gaap	Share Based Compensation ShareBasedCompensation	5271000	USD
CY2017Q1	us-gaap	Share Based Compensation ShareBasedCompensation	7124000	USD
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	3441215	shares
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1540298	shares
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	33.17
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	800000	USD
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	4882000	USD
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	4900000	USD
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	25698	shares
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	416244	shares
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	32610000	USD
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3441303	shares
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3571559	shares
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	32.27
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	34.35
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	30325000	USD
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	63150000	USD
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	3275247	shares
CY2017Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	24.34
CY2017Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	33.85
CY2017Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	45.19
CY2017Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	15447000	USD
CY2017Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P7Y6M
CY2017Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y2M12D
CY2016Q1	us-gaap	Shipping Handling And Transportation Costs ShippingHandlingAndTransportationCosts	1000000	USD
CY2017Q1	us-gaap	Shipping Handling And Transportation Costs ShippingHandlingAndTransportationCosts	1300000	USD
CY2017Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	260290	shares
CY2017Q1	us-gaap	Stockholders Equity StockholdersEquity	63585000	USD
CY2017Q1	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	USD
CY2016Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	57029575	shares
CY2017Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	57693930	shares
CY2016Q4	us-gaap	Nature Of Operations NatureOfOperations	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Nature of the Business </font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Insulet Corporation, the "Company," is primarily engaged in the development, manufacturing and sale of its proprietary Omnipod Insulin Management System (“Omnipod System”), an innovative, discreet and easy-to-use continuous insulin delivery system for people with insulin-dependent diabetes. The Omnipod System features a small, lightweight, self-adhesive disposable tubeless Omnipod device which is worn on the body for approximately three days at a time and its wireless companion, the handheld Personal Diabetes Manager ("PDM"). Conventional insulin pumps require people with insulin-dependent diabetes to learn to use, manage and wear a number of cumbersome components, including up to </font><font style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;">42</font><font style="font-family:Arial;font-size:10pt;"> inches of tubing. In contrast, the Omnipod System features only two discreet, easy-to-use devices that eliminate the need for a bulky pump, tubing and separate blood glucose meter, provides for virtually pain-free automated cannula insertion, communicates wirelessly and integrates a blood glucose meter. The Company believes that the Omnipod System’s unique proprietary design and features allow people with insulin-dependent diabetes to manage their diabetes with unprecedented freedom, comfort, convenience, and ease. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Commercial sales of the Omnipod System began in the United States in 2005. The Company sells the Omnipod System in the United States through direct sales to customers or through its distribution partners. The Omnipod System is currently available in multiple countries in Europe, as well as in Canada and Israel.</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In addition to using the Omnipod System for insulin delivery, the Company also partners with global pharmaceutical and biotechnology companies to tailor the Omnipod System technology platform for the delivery of subcutaneous drugs across multiple therapeutic areas.    </font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company acquired Neighborhood Holdings, Inc. and its wholly-owned subsidiaries (collectively, “Neighborhood Diabetes”) in </font><font style="font-family:Arial;font-size:10pt;">June 2011</font><font style="font-family:Arial;font-size:10pt;">. Through Neighborhood Diabetes, the Company provided customers with blood glucose testing supplies, traditional insulin pumps, pump supplies and pharmaceuticals and had the ability to process claims as either durable medical equipment or through pharmacy benefits. In February 2016, the Company sold Neighborhood Diabetes to Liberty Medical LLC ("Liberty Medical"). Additional information regarding the disposition and treatment of the Neighborhood Diabetes business as discontinued operations is provided in Note </font><font style="font-family:Arial;font-size:10pt;">3</font><font style="font-family:Arial;font-size:10pt;"> to these consolidated financial statements.</font></div></div>
CY2017Q1	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Reclassification of Prior Period Balances</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Certain reclassifications have been made to prior period amounts to conform to the current period financial statement presentation including reclassifying internal-use capitalized software from property and equipment to other intangible assets for the year ended December 31, 2016 upon adoption of ASU 2016-19, </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">Technical Corrections and Improvements</font><font style="font-family:Arial;font-size:10pt;">.</font></div></div>
CY2017Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates in Preparation of Financial Statements</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions in the application of certain of its significant accounting policies that may materially affect the reported amounts of assets, liabilities, equity, revenue and expenses. The most significant estimates used in these financial statements include the valuation of stock-based compensation expense, acquired businesses, accounts receivable, inventories, goodwill, deferred revenue, equity instruments, convertible debt, the lives of property and equipment and intangible assets, as well as warranty and doubtful accounts allowance reserve calculations. Actual results may differ from those estimates.</font></div></div>

Files In Submission

Name	View Source	Status
0001145197-17-000009-index-headers.html	Edgar Link	pending
0001145197-17-000009-index.html	Edgar Link	pending
0001145197-17-000009.txt	Edgar Link	pending
0001145197-17-000009-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
podd-20170331.xml	Edgar Link	completed
podd-20170331.xsd	Edgar Link	pending
podd-20170331_cal.xml	Edgar Link	unprocessable
podd-20170331_def.xml	Edgar Link	unprocessable
podd-20170331_lab.xml	Edgar Link	unprocessable
podd-20170331_pre.xml	Edgar Link	unprocessable
podd-2017x03x31_10q.htm	Edgar Link	pending
podd-exx101_2017331x10q.htm	Edgar Link	pending
podd-exx102_2017331x10q.htm	Edgar Link	pending
podd-exx103_201733110q.htm	Edgar Link	pending
podd-exx104_2017331x10q.htm	Edgar Link	pending
podd-exx105_2017331x10q.htm	Edgar Link	pending
podd-exx106_201733110q.htm	Edgar Link	pending
podd-exx107_2017331x10q.htm	Edgar Link	pending
podd-exx311_20170331x10q.htm	Edgar Link	pending
podd-exx312_20170331x10q.htm	Edgar Link	pending
podd-exx321_20170331x10q.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PODD
INSULET CORP Stock $podd

2017 Q2 Form 10-Q Financial Statement

#000114519717000009 Filed on May 09, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PODD INSULET CORP Stock $podd

2017 Q2 Form 10-Q Financial Statement

#000114519717000009 Filed on May 09, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PODD
INSULET CORP Stock $podd